Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027819 (
neuroblastoma
)
27,800
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Although the treatment strategies for
neuroblastoma
(NB) develop rapidly, a considerable number of patients could not benefit from chemotherapy. Here, we revealed a miR-129-
MYO10
axis that regulated
neuroblastoma
growth and chemosensitivity. Mechanistically,
MYO10
was up-regulated in
neuroblastoma
tissues and associated with poor overall survival. While overexpression of
MYO10
enhanced tumor growth, genetic inhibition of
MYO10
led to growth-inhibitory and chemopotentiating effects in
neuroblastoma
.
MYO10
was further identified as a target of miR-129. Our data showed that miR-129 down-regulated
MYO10
expression and subsequently suppressed cell growth. Re-expression of
MYO10
significantly rescued miR129-mediated proliferation repression and chemosensitivity. In conclusion, our results demonstrated that miR-129 inhibited
neuroblastoma
growth and potentiated chemosensitivity by targeting
MYO10
, which may represent promising targets and rational therapeutic options for
neuroblastoma
.
...
PMID:miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10. 2986 13